{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=40",
    "query": {
      "intervention": "Placebo- matched",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 7052,
    "total_pages": 706,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T02:22:40.722Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06131372",
      "title": "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Cagrilintide",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 626,
      "start_date": "2024-04-01",
      "completion_date": "2025-11-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 25,
      "location_summary": "Concord, California • Fresno, California • Palm Springs, California + 22 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06131372"
    },
    {
      "nct_id": "NCT07058077",
      "title": "A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Heterozygous Familial Hypercholesterolemia (HeFH)"
      ],
      "interventions": [
        {
          "name": "Enlicitide Decanoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 153,
      "start_date": "2025-08-21",
      "completion_date": "2037-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 8,
      "location_summary": "Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07058077"
    },
    {
      "nct_id": "NCT04532957",
      "title": "A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "KBP-7072",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "KBP Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-08-11",
      "completion_date": "2020-10-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04532957"
    },
    {
      "nct_id": "NCT03001557",
      "title": "Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irregular Sleep-Wake Rhythm Disorder"
      ],
      "interventions": [
        {
          "name": "Lemborexant 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Lemborexant 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Lemborexant 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Lemborexant 15 mg",
          "type": "DRUG"
        },
        {
          "name": "Lemborexant-matched placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "60 Years to 90 Years"
      },
      "enrollment_count": 63,
      "start_date": "2016-12-20",
      "completion_date": "2020-04-17",
      "has_results": true,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 37,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03001557"
    },
    {
      "nct_id": "NCT06628362",
      "title": "A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight or Obese",
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enicepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carmot Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 447,
      "start_date": "2024-11-21",
      "completion_date": "2026-10-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06628362"
    },
    {
      "nct_id": "NCT01314261",
      "title": "Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C",
        "Hepatitis C Virus (HCV) Infection"
      ],
      "interventions": [
        {
          "name": "ABT-267",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon (pegIFN)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABT-267",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2011-03",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01314261"
    },
    {
      "nct_id": "NCT00663169",
      "title": "Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Gouty"
      ],
      "interventions": [
        {
          "name": "canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "placebo matching canakinumab",
          "type": "OTHER"
        },
        {
          "name": "placebo matching dexamethasone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2008-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-07",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00663169"
    },
    {
      "nct_id": "NCT04098003",
      "title": "Investigation of the Gut Microbiome and Statin Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sony Tuteja",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-02-06",
      "completion_date": "2026-03-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 1,
      "location_summary": "Phildelphia, Pennsylvania",
      "locations": [
        {
          "city": "Phildelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04098003"
    },
    {
      "nct_id": "NCT03829241",
      "title": "Randomized Trial of Adult Participants With Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Troriluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 881,
      "start_date": "2019-02-19",
      "completion_date": "2020-05-08",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 53,
      "location_summary": "Little Rock, Arkansas • Colton, California • Encino, California + 48 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829241"
    },
    {
      "nct_id": "NCT03434041",
      "title": "A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "Esketamine 56 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 84 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 252,
      "start_date": "2018-05-25",
      "completion_date": "2021-04-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-11-11T02:22:40.722Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        },
        {
          "city": "Watertown",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434041"
    }
  ]
}